Fixation member assembly with bi-directionally controlled drug release
Through the design of the two-way delivery port of the spiral fixed member, the problems of drug release rate control and device strength in cardiac medical devices are solved, and the targeted delivery of therapeutic agents in the endocardial and myocardial layers are realized, reducing inflammatory response and simplifying Filling process.
Patent Information
- Application Number
- CN202411104210.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-01-31
- Filing Date
- 2019-01-29
- Publication Date
- 2024-11-19
AI Technical Summary
Prior Art In cardiac medical devices, the drug release rate of steroid elution electrodes is not controlled enough, resulting in limited delivery of therapeutic agents at the endocardial surface, which cannot effectively reduce the inflammatory response, and increasing the number of elution ports will reduce the strength of the device and Complex filling process.
Using spiral fixation members, including proximal and distal delivery ports, the two-way controlled release of therapeutic agents is achieved through electrical coupling with the lead body, ensuring targeted delivery of drugs in the endocardial and myocardial layer, reducing inflammatory responses, and Simplify the capillary filling process.
Long-term control and targeted delivery of therapeutic agents are achieved, reducing the inflammatory response, prolonging the release time of therapeutic agents, enhancing the penetration ability of the device, and reducing the amount of inflammation at the implanted site.
Smart Images

Figure CN118976199A_ABST
Abstract
Description
[0001] This invention patent application is a divisional application of the invention patent application with international application number PCT / US2019 / 015674, international application date January 29, 2019, application number 201980011028.6 entering the Chinese national phase, and name “Fixed component assembly with bidirectional controlled drug release”. Technical Field
[0002] The present disclosure relates generally to cardiac medical devices, and more particularly to methods and devices for the controlled release of therapeutic agents within cardiac tissue surrounding electrodes of cardiac medical devices. Background Art
[0003] Implantable medical devices include various devices that can provide monitoring of a patient's physiological parameters, delivery of treatments such as electrical stimulation treatments to the patient's cardiac tissue, or both. For example, an implantable medical device delivers electrical stimulation treatments and / or monitors physiological signals via one or more electrodes or sensor elements, which may be included on the housing of the device or as part of one or more elongated implantable medical leads. The implantable medical lead is configured to allow one or more electrodes and / or sensors to be positioned at a desired location for sensing or delivering stimulation. For example, an electrode or sensor is positioned at a distal portion of the lead, while a connector is positioned at a proximal portion of the lead and is connected to the implantable medical device housing, which may contain electronic circuits, such as stimulation generation and / or sensing circuits.
[0004] In order to achieve cardiac pacing, sensing, cardioversion and / or defibrillation at different locations of the heart, various types of cardiac leads have been developed, including epicardial leads, endocardial leads and coronary venous leads. Intravenous endocardial leads establish electrical contact between an electrical pulse generator such as a pacemaker or an implantable cardioverter-defibrillator and the endocardial surface of the heart, usually in the right ventricle. Endocardial leads and cardiac leads can usually be fixed in place by passive fixation mechanisms such as tines that interact with the ventricular trabeculae or active fixation mechanisms such as spirals located at the distal end of the lead. Coronary venous leads can be passed through a venous passage, into the right atrium, through the ostium of the coronary sinus, and finally reach a position where the fixation mechanism in the cardiac vein is fixed to the heart tissue.
[0005] In some examples, a leadless pacemaker can be used to sense electrical activity and / or deliver therapeutic signals to the heart. The leadless pacemaker can include one or more electrodes on its housing to deliver therapeutic electrical signals and / or sense intrinsic depolarization of the heart. The leadless pacemaker can be positioned inside or outside the heart and, in some examples, can be anchored to the wall of the heart via a fixation mechanism.
[0006] Various characteristics of the leads, electrodes, and tissues that interface with the electrodes will result in characteristic impedances, stimulation thresholds, and sensing thresholds. The stimulation threshold is the energy required for the stimulation pulse to depolarize or "capture" the cardiac tissue. One factor that may affect the stimulation threshold, particularly during the first few weeks after implantation of the lead, is the body's natural immune response to the lead as a foreign body. The presence of the lead activates an immune response that ultimately leads to fibrotic encapsulation of the lead and its electrode. Since fibrotic tissue is not excitable tissue, the stimulation threshold can be maintained due to the reduced electrical properties of the electrode-tissue interface.
[0007] In order to reduce the inflammatory response, medical leads that can elute anti-inflammatory steroids have been developed. Steroid eluting leads may require a monolithic controlled release device (MCRD) to contain steroids, and then slowly dissolve the water-soluble steroids into the surrounding tissues. However, a limitation of steroid eluting electrodes or MCRDs is that, since the drug is only present at the endocardial surface, the eluted drug only treats a relatively limited volume of tissue. Other devices have been proposed, in which the therapeutic agent stored in the luminal space of the spiral fixing member is released by multiple elution ports positioned along the spiral fixing member that is fluidly connected to the luminal space, which allows the therapeutic agent to be directly delivered to the tissue that is penetrated by the spiral fixing member and surrounds the spiral fixing member. However, although current technology shows that the release rate of the therapeutic agent can be controlled by changing the number of elution ports included along the electrode, increasing the number of elution ports increases the rate of reagent release, thereby reducing the length of time that the therapeutic agent can be delivered to the tissue. In addition, when multiple elution ports are included on the fixing member, it becomes complicated to use the therapeutic agent to capillary fill the device. Therefore, there is a need for improvements that enable capillary filling of a helical fixation member with a therapeutic agent, as well as long-term controlled and targeted delivery of steroid eluate from the helical fixation member. Summary of the invention
[0008] In general, the present disclosure is intended to provide long-term controlled and targeted delivery of steroid eluate from an electrode to tissue at an implantation site. In one example, the present disclosure relates to an implantable medical lead, comprising: an elongated lead body extending from a proximal end to a distal end; a fixation member having a proximal end and a distal end, the proximal end of the fixation member being configured to be electrically coupled to the distal end of the lead body, the helical fixation member comprising: a first delivery port and a second delivery port for releasing a therapeutic agent from the fixation member to tissue of a patient, wherein the first delivery port is positioned along the proximal end of the fixation member to deliver the therapeutic agent to endothelial cells along the endothelial layer of the tissue, the second delivery port is positioned along the distal end of the fixation member and is spaced a distance from the first delivery port to deliver the therapeutic agent to myocardial tissue within the myocardium of the tissue, and wherein no delivery port is positioned within the distance spaced between the second delivery port and the first delivery port.
[0009] In another example, the present disclosure relates to an implantable medical device comprising: a sensing module that senses cardiac signals; a stimulation generator that delivers cardiac therapy in response to the sensed cardiac signals; and a fixing member having a proximal end and a distal end, the proximal end of the helical fixing member being configured to be electrically coupled to the distal end of a lead body, the helical fixing member comprising: a first delivery port and a second delivery port, the first delivery port and the second delivery port being used to release a therapeutic agent from the fixing member to tissue of a patient, wherein the first delivery port is positioned along the proximal end of the fixing member to deliver the therapeutic agent to endothelial cells along the endothelial layer of the tissue, the second delivery port is positioned along the distal end of the fixing member and is spaced a distance from the first delivery port to deliver the therapeutic agent to myocardial tissue within the myocardium of the tissue, and wherein no delivery port is positioned within the distance separating the second delivery port from the first delivery port.
[0010] In another example, the present disclosure is directed to a fixation member for use with an implantable medical device, the fixation member comprising:
[0011] a helical body having a proximal end and a distal end and configured to be fixedly positioned within cardiac tissue;
[0012] an inner lumen extending within the helical body and extending from the proximal end to the distal end;
[0013] a first delivery port positioned along the proximal end of the helical body and in fluid communication with the lumen to deliver a therapeutic agent within the lumen to cardiac tissue; and
[0014] A second delivery port is positioned along the distal end of the spiral body and is in communication with the lumen fluid to deliver a therapeutic agent to cardiac tissue, the second delivery port being spaced a distance from the first delivery port such that the therapeutic agent is delivered to endothelial cells along the endothelial layer of the cardiac tissue via the first delivery port and the therapeutic agent is delivered to myocardial tissue within the myocardium of the cardiac tissue via the second delivery port, and wherein no delivery port is positioned within the distance between the first delivery port and the second delivery port.
[0015] These and other aspects of the disclosure will become apparent from the following detailed description. However, in no event should the above summary be construed as a limitation on the claimed subject matter, which is defined solely by the appended claims, as may be amended during prosecution. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Throughout the specification, reference is made to the accompanying drawings, wherein like reference numerals refer to like elements, and wherein:
[0017] Figure 1 is a conceptual diagram illustrating an exemplary medical device system for delivering a therapeutic agent consistent with examples of the present disclosure.
[0018] Figure 2 is shown in more detail Figure 1 Conceptual diagram of an implantable medical device (IMD) and leads of the system shown.
[0019] Figure 3 is a conceptual diagram showing another example of a medical device system. Figure 1-2 The system is similar to that of , but includes two leads instead of three.
[0020] Figure 4 is a functional block diagram illustrating one exemplary configuration of an IMD according to examples of the present disclosure.
[0021] Figure 5 is a functional block diagram illustrating an exemplary configuration of a programmer according to examples of the present disclosure.
[0022] Figure 6 is a plan view of an implantable medical lead including a helical fixation member for controlled bidirectional delivery of a therapeutic agent according to an example of the present disclosure.
[0023] Figure 7 is a schematic diagram of a helical fixation member for controlled bidirectional delivery of a therapeutic agent according to an example of the present disclosure.
[0024] Figure 8 is a schematic diagram of a helical fixation member for controlled bidirectional delivery of a therapeutic agent according to an example of the present disclosure.
[0025] Fig. 9 is a conceptual diagram illustrating an exemplary medical device system for delivering a therapeutic agent consistent with examples of the present disclosure.
[0026] Fig.10 is an example according to the present disclosure Fig. 9 Conceptual illustration of an exemplary medical device.
[0027] Fig.11 is a functional block diagram illustrating an exemplary configuration of a leadless pacemaker device according to examples of the present disclosure. DETAILED DESCRIPTION
[0028] The technology described in the present disclosure provides for providing long-term control and targeted delivery of steroid eluate and enables the improvement of capillary filling of spiral fixing member with therapeutic agent.For example, the implantable medical device of the present disclosure comprises spiral fixing member, and this spiral fixing member comprises proximal delivery port and distal delivery port, and both are communicated with the inner cavity fluid in the spiral fixing member, and this inner cavity forms the inner diameter of spiral fixing member.In a kind of example, proximal delivery port and distal delivery port can have the same diameter, and therefore release the therapeutic agent such as steroid at approximately the same rate.But, in some examples, the diameter of proximal delivery port and distal delivery port can have different values, and therefore release the therapeutic agent at different rates.
[0029] As a result, once the helical fixation member is secured within tissue such as cardiac tissue, a therapeutic agent such as a steroid can be bidirectionally released from the helical fixation member 310 within the cardiac tissue through the proximal delivery port 320 and the distal delivery port 322. More specifically, to enable controlled bidirectional release of the therapeutic agent, the proximal delivery port is spaced a distance from the distal delivery port, wherein no additional delivery port is positioned within the distance separating the distal delivery port from the proximal delivery port.
[0030] According to an example of the present disclosure, the distance between the proximal delivery port and the distal delivery port of the electrode is configured so that the proximal delivery port of the helical fixation member is positioned within the endothelial layer of the tissue and the distal delivery port is positioned within the myocardial tissue layer below the endothelial layer.
[0031] Thus, the helical fixation member of the present disclosure enables more targeted and controlled delivery of therapeutic agents near the proximal electrode of the cardiac tissue and / or the top surface of the cardiac tissue via the proximal delivery port at the implantation site and in the first fusion zone located within the endothelial layer of the tissue. In addition, the therapeutic agent is delivered via the distal delivery port at the distal end of the spiral electrode and in a separate second fusion zone within the myocardial tissue. Since the therapeutic agent is not delivered directly to the myocardial tissue along the space between the proximal delivery port and the distal delivery port, but is controlled to be delivered only in the first fusion zone and the second fusion zone, the present disclosure is configured to deliver the therapeutic agent using a more controlled bidirectional release of the therapeutic agent.
[0032] In another example, the diameters of the proximal and distal delivery ports may have different values, so that the amount of therapeutic agent delivered via one delivery port may be different relative to the other port. For example, it may be desirable to deliver a therapeutic agent from the proximal delivery port at a greater rate than the amount delivered from the distal delivery port, resulting in a greater amount of agent delivered to the first fusion region than the amount of therapeutic agent delivered to the second fusion region. Therefore, in this example, the diameter of the proximal delivery port will be configured to be greater than the diameter of the distal delivery port. In another example, it may be desirable to deliver a therapeutic agent from the proximal delivery port at a smaller rate than the amount delivered from the distal delivery port, resulting in a greater amount of agent delivered to the second fusion region than the amount of therapeutic agent delivered to the first fusion region. Therefore, in this example, the diameter of the proximal delivery port will be configured to be smaller than the diameter of the distal delivery port.
[0033] By being configured to enable a more controlled bi-directional release of the therapeutic agent, the present disclosure provides a more targeted and controlled method to ensure delivery of the therapeutic agent while minimizing the inflammatory response in specific targeted areas of the tissue where inflammation is most likely to occur, such as within the endothelial layer of the tissue. By enabling controlled delivery of the therapeutic agent so that it is delivered within two separate specific fusion areas, the total fusion area can be reduced and more targeted, thereby minimizing the amount of therapeutic agent delivered, extending the period of time over which the therapeutic agent continues to be released, and enabling a more controlled and targeted reduction in inflammation that may occur.
[0034] Furthermore, this controlled bidirectional release of the present disclosure minimizes the damage to the strength of the helical fixation member that would occur if the number of delivery ports were increased to greater than the two delivery ports described, thereby enhancing the ability of the helical fixation member to more easily penetrate the tissue of the implant site and further reducing the amount of inflammation that occurs in specific selected targeted problem areas of the implant site. Furthermore, by spacing only the proximal delivery port from the distal delivery port by the aforementioned distance, with no delivery port within the distance between the proximal delivery port and the distal delivery port, delivery of the therapeutic agent according to the present disclosure simplifies capillary filling of the helical fixation member.
[0035] Figure 1 is a conceptual diagram showing an exemplary implantable medical device system according to the present disclosure, which may include bidirectional controlled release of a therapeutic agent. Figure 1 As shown, a system 10 with bidirectional controlled release of a therapeutic agent according to the present disclosure may include an IMD 16 coupled to leads 18, 20, and 22, and a programmer 24. For example, the IMD 16 may be an implantable pacemaker, cardioverter, and / or defibrillator that provides electrical signals to the heart 12 of the patient 16 via electrodes coupled to one or more of the leads 18, 20, and 22.
[0036] Leads 18, 20, 22 extend into heart 12 of patient 16 to sense electrical activity of heart 12 and / or deliver electrical stimulation to heart 12. Figure 1 In the example shown, the right ventricle (RV) lead 18 extends through one or more veins (not shown), the superior vena cava (not shown), and the right atrium 26, and into the right ventricle 28. The left ventricle (LV) coronary sinus lead 20 extends through one or more veins, the vena cava, the right atrium 26, and into the coronary sinus 30 to a region adjacent to the free wall of the left ventricle 32 of the heart 12. The right atrium (RA) lead 22 extends through one or more veins and the vena cava, and into the right atrium 26 of the heart 12.
[0037] IMD 16 can sense electrical signals associated with depolarization and repolarization of heart 12 via electrodes coupled to at least one of leads 18, 20, 22. In some examples, IMD 16 provides pacing pulses to heart 12 based on the electrical signals sensed within heart 12. The configuration of the electrodes used by IMD 16 for sensing and pacing can be unipolar or bipolar. IMD 16 can also provide defibrillation therapy and / or cardioversion therapy via electrodes located on at least one of leads 18, 20, 22. IMD 16 can detect arrhythmias of heart 12, such as fibrillation of ventricles 28 and 32, and deliver defibrillation therapy to heart 12 in the form of electrical pulses. In some examples, IMD 16 can be programmed to gradually deliver therapy, such as pulses with increasing energy levels, until fibrillation of heart 12 stops. IMD 16 detects fibrillation using one or more fibrillation detection techniques known in the art.
[0038] In some examples, programmer 24 may be a handheld computing device or a computer workstation capable of communicating with IMD 16. Programmer 24 may include a user interface for receiving input from a user, and may include, for example, a keypad and a display, such as, for example, a cathode ray tube (CRT) display, a liquid crystal display (LCD), or a light emitting diode (LED) display. The keypad may take the form of an alphanumeric keypad or a simplified set of keys associated with specific functions. Programmer 24 may additionally or alternatively include a peripheral pointing device such as a mouse, via which a user may interact with the user interface. In some embodiments, the display of programmer 24 may include a touch screen display, and the user may interact with programmer 24 via the display.
[0039] A user, such as a physician, technician, surgeon, or other clinician, may interact with programmer 24 to communicate with IMD 16. For example, a user may interact with programmer 24 to retrieve physiological or diagnostic information from IMD 16. A user may also interact with programmer 24 to program IMD 16, e.g., to select values for operating parameters of IMD 16.
[0040] For example, the user may use programmer 24 to retrieve information from IMD 16 related to the rhythm of heart 12, changes in rhythm over time, or the onset of an arrhythmia. As another example, the user may use programmer 24 to retrieve information from IMD 16 regarding other sensed physiological parameters of patient 14, such as intracardiac or intravascular pressure, activity, posture, respiration, or thoracic impedance. As another example, the user may use programmer 24 to obtain information from IMD 16 regarding the performance or integrity of IMD 16 or other components of system 10, such as a power supply or leads 18, 20, and 22 of IMD 16.
[0041] The user may use programmer 24 to program a therapy session, select electrodes for delivering a defibrillation shock, select a waveform for a defibrillation shock, or select or configure a fibrillation detection algorithm for IMD 16. The user may also use programmer 24 to program other aspects of therapy, such as cardioversion or pacing therapy, provided by IMD 16. In some examples, the user may activate certain features of IMD 16 by inputting a single command through programmer 24, such as pressing a single key or a combination of keys of a keyboard or performing a single click-selection action with a pointing device.
[0042] IMD 16 and programmer 24 may communicate via wireless communications using any technique known in the art. Examples of communication techniques may include, for example, low frequency or radio frequency (RF) telemetry, although other techniques are also contemplated. In some examples, programmer 24 may include a programming head that may be placed proximate to the patient's body near the implant site of IMD 16 in order to improve the quality or safety of communication between IMD 16 and programmer 24.
[0043] Figure 2 is shown in more detail Figure 1 A conceptual diagram of an implantable medical device (IMD) and leads of the system shown. Figure 2 As shown, leads 18, 20, 22 may be electrically coupled to a stimulation generator, a sensing module, or other modules of IMD 16 via connector block 34. In some examples, proximal ends of leads 18, 20, 22 may include electrical contacts that are electrically coupled to respective electrical contacts within connector block 34. Additionally, in some examples, leads 18, 20, 22 may be mechanically coupled to connector block 34 by means of set screws, connecting pins, or other suitable mechanical coupling mechanisms.
[0044] Each of the leads 18, 20, 22 includes an elongated insulated lead body that carries a plurality of concentrically coiled conductors separated from one another by a tubular insulating sleeve. In the example shown, a pressure sensor 38 and bipolar electrodes 40 and 42 are located near the distal end of lead 18. In addition, bipolar electrodes 44 and 46 are located near the distal end of lead 20, and bipolar electrodes 48 and 50 are located near the distal end of lead 22.
[0045] Electrodes 40, 44, and 48 may take the form of ring electrodes, and electrodes 42, 46, and 50 may take the form of extendable spiral tip electrodes that are retractably mounted in insulated electrode heads 52, 54, 56, respectively. Each of electrodes 40, 42, 44, 46, 48, and 50 may be electrically coupled to a respective one of the coiled conductors within the lead body of its associated lead 18, 20, 22, and thus to a respective electrical contact on the proximal end of the lead 18, 20, 22.
[0046] Electrodes 40, 42, 44, 46, 48, and 50 may sense electrical signals associated with depolarization and repolarization of heart 12. The electrical signals are directed to IMD 16 via corresponding leads 18, 20, 22. In some examples, IMD 16 also delivers pacing pulses via electrodes 40, 42, 44, 46, 48, and 50 to cause depolarization of cardiac tissue of heart 12. Figure 2As shown, in some examples, IMD 16 includes one or more housing electrodes, such as housing electrode 58, which can be integrally formed with an outer surface of a hermetically sealed housing 60 of IMD 16 or otherwise coupled to housing 60. In some examples, housing electrode 58 is defined by an uninsulated portion of an outwardly facing portion of housing 60 of IMD 16. Other partitions between insulated and uninsulated portions of housing 60 can be used to define two or more housing electrodes. In some examples, housing electrode 58 includes substantially all of housing 60. Any of electrodes 40, 42, 44, 46, 48, and 50 can be used in conjunction with housing electrode 58 for unipolar sensing or pacing. As described with reference to Figure 4 As described in further detail, housing 60 may enclose a stimulation generator for producing cardiac pacing pulses and defibrillation or cardioversion shocks, as well as a sensing module for monitoring the patient's heart rhythm.
[0047] Leads 18, 20, 22 also include elongated electrodes 62, 64, 66, respectively, which may take the form of coils. IMD 16 may deliver defibrillation shocks to heart 12 via any combination of elongated electrodes 62, 64, 66 and housing electrode 58. Electrodes 58, 62, 64, 66 may also be used to deliver cardioversion pulses to heart 12. Electrodes 62, 64, 66 may be made of any suitable conductive material, such as, but not limited to, platinum, platinum alloys, or other known materials that may be used in implantable defibrillation electrodes.
[0048] Figure 1 and 2 The configuration of the treatment system 10 shown in is only one example. In other examples, as Figure 1 In addition to or in lieu of the transvenous leads 18, 20, 22 shown in , the therapy system may include epicardial leads and / or patch electrodes. Further, IMD 16 need not be implanted in patient 14. In examples where IMD 16 is not implanted in patient 14, IMD 16 may deliver defibrillation shocks and other therapies to heart 12 via transcutaneous leads extending through the patient's skin 14 to a plurality of locations within or outside of heart 12.
[0049] In other examples of treatment systems for providing electrical stimulation therapy to heart 12, the treatment system may include any suitable number of leads coupled to IMD 16, and each lead may extend to any location within or near heart 12. For example, other examples of treatment systems may include, for example, Figure 1 and 2, and an additional lead located within or near left atrium 36. As another example, other examples of therapy systems may include a single lead extending from IMD 16 into right atrium 26 or into right ventricle 28, or two leads extending into corresponding ones of right ventricle 26 and right atrium 28. Figure 3 An example of such a treatment system is shown in .
[0050] Figure 3 is a conceptual diagram showing another example of a medical device system. Figure 1-2 is similar to the system of , but includes two leads instead of three. Figure 3 As shown, a medical device system 70 that may include bidirectional controlled release of a therapeutic agent according to the present disclosure may include only leads 18, 22 implanted within the right ventricle 28 and right atrium 26, respectively. Figure 3 The exemplary medical device system 70 shown may be used to provide defibrillation and pacing pulses to the heart 12 .
[0051] Figure 4 is a functional block diagram showing an exemplary configuration of an exemplary implantable medical device according to the present disclosure. Figure 4 As shown, according to an example of the present disclosure, IMD 16 may include processor 80, memory 82, stimulation generator 84, sensing module 86, telemetry module 88, and power source 90. Memory 82 includes computer-readable instructions that, when executed by processor 80, cause IMD 16 and processor 80 to perform various functions attributed to IMD 16 and processor 80 as described herein. Memory 82 may include any volatile, nonvolatile, magnetic, optical, or electrical media, such as random access memory (RAM), read-only memory (ROM), nonvolatile RAM (NVRAM), electrically erasable programmable ROM (EEPROM), flash memory, or any other digital media.
[0052] The processor 80 may include any one or more of a microprocessor, a controller, a digital signal processor (DSP), an application specific integrated circuit (ASIC), a field programmable gate array (FPGA), or an equivalent discrete or integrated logic circuit. In some examples, the processor 80 may include multiple components, such as any combination of one or more microprocessors, one or more controllers, one or more DSPs, one or more ASICs, or one or more FPGAs and other discrete or integrated logic circuits. The functions attributed to the processor 80 herein may be embodied as software, firmware, hardware, or any combination thereof. The processor 80 controls the stimulation generator 84 to deliver stimulation therapy to the heart 12 according to one or more selected treatment programs, which may be stored in the memory 82. Specifically, the processor 44 may control the stimulation generator 84 to deliver electrical pulses having an amplitude, pulse width, frequency, or electrode polarity specified by the selected one or more treatment programs.
[0053] Stimulation generator 84 is electrically coupled to electrodes 40, 42, 44, 46, 48, 50, 58, 62, 64, and 66, e.g., via conductors of respective leads 18, 20, 22 or, in the case of housing electrode 58, via electrical conductors disposed within housing 60 of IMD 16. Stimulation generator 84 may be configured to generate and deliver electrical stimulation therapy to heart 12. For example, stimulation generator 84 may deliver a defibrillation shock to heart 12 via at least two electrodes 58, 62, 64, 66. Stimulation generator 84 may deliver pacing pulses via ring electrodes 40, 44 coupled to leads 18, 20, and 22, respectively, and / or via helical electrodes 42, 46, and 50 via leads 18, 20, and 22, respectively. In some examples, stimulation generator 84 delivers pacing, cardioversion, or defibrillation stimulation in the form of electrical pulses. In other examples, stimulation generator 84 may deliver one or more of these types of stimulation in the form of other signals, such as sine waves, square waves, or other substantially continuous time signals.
[0054] Stimulation generator 84 may include a switch module, and processor 80 may use the switch module to select, for example, via a data / address bus, which of the available electrodes is used to deliver a defibrillation shock or a pacing pulse. The switch module may include a switch array, a switch matrix, a multiplexer, or any other type of switching device suitable for selectively coupling stimulation energy to selected electrodes.
[0055] The sensing module 86 monitors a signal from at least one of the electrodes 40, 42, 44, 46, 48, 50, 58, 62, 64, or 66 to monitor the electrical activity of the heart 12, for example, via an electrocardiogram (ECG) signal. The sensing circuit 86 may also include a switch module to select which available electrode to use for sensing cardiac activity. In some examples, the processor 80 may select an electrode that functions as a sensing electrode via a switch module within the sensing module 86, for example, by providing a signal via a data / address bus. In some examples, the sensing module 86 includes one or more sensing channels, each of which may include an amplifier. In response to a signal from the processor 80, the switch module within the sensing module 86 may couple an output from a selected electrode to one of the sensing channels.
[0056] In some examples, one channel of sensing module 86 may include an R-wave amplifier that receives signals from electrodes 40 and 42 that are used for pacing and sensing in the right ventricle 28 of heart 12. Another channel may include another R-wave amplifier that receives signals from electrodes 44 and 46 that are used for pacing and sensing near the left ventricle 28 of heart 12. In some examples, the R-wave amplifier may take the form of an automatic gain controlled amplifier that provides an adjustable sensing threshold that is a function of the R-wave amplitude of the measured heart rhythm.
[0057] In addition, in some examples, one channel of the sensing module 86 may include a P-wave amplifier that receives signals from the electrodes 48 and 50 that are used for pacing and sensing in the right atrium 26 of the heart 12. In some examples, the P-wave amplifier may take the form of an automatic gain control amplifier that provides an adjustable sensing threshold that is a function of the P-wave amplitude of the measured heart rhythm. Examples of R-wave amplifiers and P-wave amplifiers are described in U.S. Patent No. 5,117,824, entitled "APPARATUS FOR MONITORING ELECTRICAL PHYSIOLOGIC SIGNALS," issued to Keimel et al. on June 2, 1992, and the entire text of the patent is incorporated herein by reference. Other amplifiers may also be used. In addition, in some examples, one or more sensing channels of sensing module 86 may be selectively connected to shell electrode 58, or elongated electrode 62, 64, or 66, together with or in lieu of one or more of electrodes 40, 42, 44, 46, 48, or 50, for example for unipolar sensing of R waves or P waves in any chamber 26, 28, or 32 of heart 12.
[0058] In some examples, the sensing module 86 includes a channel including an amplifier having a relatively wide passband compared to an R wave or P wave amplifier. Signals from selected sensing electrodes selected for coupling to the wideband amplifier may be provided to a multiplexer and subsequently converted by an analog-to-digital converter into a multi-bit digital signal for storage in the memory 82 as an electrogram (EGM). In some examples, the storage of such an EGM in the memory 82 may be under the control of a direct memory access circuit. The processor 80 may employ digital signal analysis techniques to characterize the digitized signals stored in the memory 82 to detect and classify the patient's heart rhythm from the electrical signals. The processor 80 may detect and classify the heart rhythm of the patient 14 by employing any of a number of signal processing methods known in the art.
[0059] If the IMD 16 is configured to generate and deliver pacing pulses to the heart 12, the processor 80 may include a pacemaker timing and control module, which may be embodied in hardware, firmware, software, or any combination thereof. The pacemaker timing and control module may include a dedicated hardware circuit such as an ASIC that is separate from other processor 80 components such as a microprocessor, or may include a software module executed by a component of the processor 80, which may be a microprocessor or an ASIC. The pacemaker timing and control module may include a programmable counter that controls basic time intervals associated with DDD, VVI, DVI, VDD, AAI, DDI, DDDR, VVIR, DVIR, VDDR, AAIR, DDIR, and other single-chamber and dual-chamber pacing modes. In the above pacing modes, "D" may represent dual chambers, "V" may represent ventricles, "I" may represent disabled pacing (e.g., no pacing), and "A" may represent atria. The first letter in the pacing mode may indicate the chamber that was regulated, the second letter may indicate the chamber in which the electrical signal was sensed, and the third letter may indicate the chamber in which the response to the sensing was provided.
[0060] The intervals defined by the pacemaker timing and control module within the processor 80 may include atrial and ventricular pacing escape intervals, refractory periods during which the sensed P waves and R waves are ineffective for restarting the timing of the escape intervals, and the pulse widths of the pacers. As another example, the pacing timing and control module may define blanking periods and provide signals from the sensing module 86 to blank one or more channels, such as amplifiers, for a period of time during and after the delivery of electrical stimulation to the heart 12. The duration of these intervals may be determined by the processor 80 in response to data stored in the memory 82. The pacemaker timing and control module of the processor 80 may also determine the amplitude of the cardiac pacing pulses.
[0061] During pacing, an escape interval counter within a pacemaker timing / control module of processor 80 may be reset when R and P waves are sensed. Stimulation generator 84 may include pacemaker output circuits that are selectively coupled, for example, via a switch module, to any combination of electrodes 40, 42, 44, 46, 48, 50, 58, 62, or 66 that are suitable for delivering bipolar or unipolar pacing pulses to one of the chambers of heart 12. Processor 80 may reset the escape interval counter when stimulation generator 84 generates a pacing pulse, thereby controlling the basic timing of cardiac pacing functions including antiarrhythmic pacing.
[0062] When reset by the sensed R and P waves, the count values present in the escape interval counter can be used by the processor 80 to measure the duration of the RR interval, PP interval, PR interval, and RP interval, which measurements can be stored in the memory 82. The processor 80 can use the counts in the interval counter to detect tachyarrhythmic events such as ventricular fibrillation events or ventricular tachycardia events. Upon detecting a threshold number of tachyarrhythmic events, the processor 80 can identify whether there is a tachyarrhythmic episode such as a ventricular fibrillation episode, a ventricular tachycardia episode, or a non-sustained tachycardia (NST) episode.
[0063] In some examples, processor 80 may operate as an interrupt driven device and respond to interrupts from a pacemaker timing and control module, where the interrupts may correspond to the occurrence of sensed P and R waves and the generation of cardiac pacing pulses. Any necessary mathematical calculations performed by processor 80 and any updates of values or intervals controlled by the pacemaker timing and control module of processor 80 may be performed following such interrupts. A portion of memory 82 may be configured as a plurality of circular buffers capable of holding a series of measured intervals that processor 80 may analyze in response to the occurrence of a rate or sensing interrupt to determine whether the patient's heart 12 is currently exhibiting an atrial or ventricular tachyarrhythmia.
[0064] In some examples, the arrhythmia detection method may include any suitable tachyarrhythmia detection algorithm. In one example, the processor 80 may utilize all or a subset of the rule-based detection methods described in U.S. Pat. No. 5,545,186, issued on Aug. 13, 1996 to Olson et al., entitled “PRIORITIZED RULE BASED METHOD AND APPARATUS FOR DIAGNOSIS AND GREATMENT OF ARRHYTHMIAS,” or U.S. Pat. No. 5,755,736, issued on May 26, 1998 to Gillberg et al., entitled “PRIORITIZED RULEBASED METHOD AND APPARATUS FOR DIAGNOSIS AND TREATMENT OF ARRHYTHMIAS.” US Patent No. 5,545,186 to Olson et al. and US Patent No. 5,545,186 to Gillberg et al. are incorporated herein by reference in their entirety. However, in other examples, processor 80 may also employ other arrhythmia detection methods.
[0065] In the examples described herein, the processor 80 can identify the presence of an atrial or ventricular arrhythmia attack by detecting a series of tachyarrhythmia events indicating a tachyarrhythmia or an average rate of consecutive short RR or PP intervals (e.g., the duration of the RR or PP interval is less than or equal to a threshold). The threshold for determining the RR or PP interval indicating a tachyarrhythmia event can be stored in the memory 82 of the IMD 16. In addition, the number of tachyarrhythmia events detected to confirm the presence of a tachyarrhythmia attack can be stored in the memory 82 as a number of detection intervals (NID) threshold. In some examples, the processor 80 can also identify the presence of a tachyarrhythmia attack by detecting variable coupling intervals between R waves of the cardiac signal. For example, if the intervals between consecutive tachyarrhythmia events change by a specific percentage, or the difference between the coupling intervals within a predetermined number of consecutive cycles is higher than a given threshold, the processor 80 can determine that a tachyarrhythmia is present.
[0066] If the processor 80 detects an atrial or ventricular tachyarrhythmia based on signals from the sensing module 86 and an anti-tachyarrhythmia pacing regimen is desired, the processor 80 may load the generated timing intervals for controlling the anti-tachyarrhythmia pacing therapy of the stimulation generator 84 into the pacemaker timing and control module to control the operation of the escape interval counter therein and define a refractory period during which detection of R waves and P waves is ineffective for restarting the escape interval counter.
[0067] If the IMD 16 is configured to generate and deliver a defibrillation shock to the heart 12, the stimulation generator 84 may include a high voltage charging circuit and a high voltage output circuit. In the event that a cardioversion or defibrillation shock is required to be generated, the processor 80 may use an escape interval counter to control the timing of such cardioversion and defibrillation shocks, as well as the associated refractory period. In response to the detection of atrial or ventricular fibrillation or tachyarrhythmia requiring a cardioversion pulse, the processor 80 may activate a cardioversion / defibrillation control module, which, like a pacemaker timing and control module, may be a hardware component of the processor 80 and / or a firmware or software module executed by one or more hardware components of the processor 80. The cardioversion / defibrillation control module may activate charging of a high voltage capacitor of the high voltage charging circuit of the stimulation generator 84 under control of a high voltage charging control line.
[0068] The processor 80 may monitor the voltage on the high voltage capacitor, for example, via a voltage charge and potential (VCAP) line. In response to the voltage on the high voltage capacitor reaching a predetermined value set by the processor 80, the processor 80 may generate a logic signal to terminate charging. Thereafter, the timing of the delivery of defibrillation or cardioversion pulses by the stimulation generator 84 is controlled by the cardioversion / defibrillation control module of the processor 80. After performing fibrillation or tachycardia therapy, the processor 80 may return the stimulation generator 84 to the cardiac pacing function and wait for the next consecutive interruption due to pacing or sensed atrial or ventricular depolarization.
[0069] Stimulation generator 84 can deliver a cardioversion or defibrillation shock with the aid of an output circuit that determines whether to deliver a monophasic or biphasic pulse, whether housing electrode 58 is used as a cathode or anode, and which electrodes are involved in the cardioversion or defibrillation shock. This functionality can be provided by one or more switches or switch modules of stimulation generator 84.
[0070] Telemetry module 88 includes any suitable hardware, firmware, software, or any combination thereof, for communicating with a programmer 24 ( Figure 1) or another device such as a cellular telephone. Under the control of processor 80, telemetry module 88 may receive downlink telemetry from programmer 24 and send uplink telemetry to programmer 24 via an antenna, which may be an internal antenna and / or an external antenna. Processor 80 may provide data to be uploaded to programmer 24 and control signals for telemetry circuitry within telemetry module 88, for example, via an address / data bus. In some examples, telemetry module 88 may provide received data to processor 80 via a multiplexer.
[0071] In some examples, processor 80 may transmit atrial and ventricular cardiac signals (e.g., electrocardiogram signals) generated by atrial and ventricular sense amplifier circuits within sensing module 86 to programmer 24. Programmer 24 may interrogate IMD 16 to receive the cardiac signals. Processor 80 may store the cardiac signals in memory 82 and retrieve the stored cardiac signals from memory 82. Processor 80 may also generate and store marker codes indicating different cardiac episodes detected by sensing module 86 and transmit the marker codes to programmer 24. An exemplary pacemaker with marker channel capability is described in U.S. Patent No. 4,374,382, issued to Markowitz on February 15, 1983, entitled "MARKER CHANNELTELEMETRY SYSTEM FOR A MEDICAL DEVICE."
[0072] The various components of IMD 16 are coupled to a power source 90, which may include rechargeable or non-rechargeable batteries. Non-rechargeable batteries may be selected to last up to several years, while rechargeable batteries may be inductively charged from an external device, such as on a daily or weekly basis.
[0073] Figure 5 is a functional block diagram showing an exemplary configuration of a programmer according to an example of the present disclosure. Figure 5 As shown, according to one example, programmer 24 may include a processor 100, a memory 102, a user interface 104, a telemetry module 106, and a power source 108. Programmer 24 may be a dedicated hardware device with dedicated software for programming IMD 16. Alternatively, programmer 24 may be an off-the-shelf computing device that runs an application that enables programmer 24 to program IMD 16.
[0074] A user may use programmer 24 to select a therapy program (e.g., a set of stimulation parameters), create a new therapy program, modify a therapy program by adjusting it individually or as a whole, or transfer a new program to a device such as IMD 16 ( Figure 1) or other medical devices. A clinician may interact with programmer 24 via user interface 104, which may include a display for presenting a graphical user interface to the user, and a keypad or other mechanism for receiving input from the user.
[0075] Processor 100 may take the form of one or more microprocessors, DSPs, ASICs, FPGAs, programmable logic circuits, etc., and the functions attributed to processor 100 herein may be embodied in hardware, firmware, software, or any combination thereof. Memory 102 may store instructions that cause processor 100 to provide the functions attributed to programmer 24 herein, as well as information used by processor 100 to provide the functions attributed to programmer 24 herein. Memory 102 may include any fixed or removable magnetic, optical, or electrical medium, such as RAM, ROM, CD-ROM, hard or floppy disks, EEPROM, etc. Memory 102 may also include a removable memory portion that may be used to provide memory updates or increases in memory capacity. Removable memory may also allow patient data to be easily transferred to another computing device, or removed prior to programming of another patient for treatment using programmer 24. Memory 102 may also store information that controls the delivery of therapy performed by IMD 16, such as stimulation parameter values.
[0076] Programmer 24 may communicate wirelessly with IMD 16, such as using RF communication or proximal sensing interaction. Such wireless communication may be performed using telemetry module 102, which may be coupled to an internal antenna or an external antenna. Figure 2 As described above, the external antenna coupled to programmer 24 may correspond to a programming head that may be placed over heart 12. Telemetry module 102 may be similar to IMD 16 ( Figure 4 )'s telemetry module 88.
[0077] Telemetry module 102 may also be configured to communicate with another computing device via wireless communication techniques, or directly through a wired connection. Examples of local wireless communication techniques that may be used to facilitate communication between programmer 24 and another computing device include RF communications according to the 802.11 or Bluetooth specification sets, infrared communications such as according to the IrDA standard, or other standard or proprietary telemetry protocols. In this manner, other external devices are able to communicate with programmer 24 without the need to establish a secure wireless connection.
[0078] Power supply 108 delivers operating power to components of programmer 24 and may include a battery and a power generation circuit for generating operating power. In some embodiments, the battery may be rechargeable to allow for extended operation. Charging may be accomplished by electrically coupling power supply 108 to a cradle or plug that is connected to an alternating current (AC) outlet. Additionally or alternatively, recharging may be accomplished by proximal inductive interaction between an external charger and an inductive charging coil within programmer 24. In other embodiments, conventional batteries (e.g., nickel-cadmium or lithium-ion batteries) may be used. In addition, programmer 24 may be directly coupled to an AC power outlet to power programmer 24. Power supply 104 may include circuitry for monitoring the remaining power within the battery. In this manner, user interface 104 may provide a current battery charge indicator or a low battery charge indicator when the battery needs to be replaced or recharged. In some cases, power supply 108 is capable of estimating the remaining operating time using the current battery.
[0079] Refer again Figure 4 , processor 80 of IMD 16 may detect a tachyarrhythmia episode, such as ventricular fibrillation, ventricular tachycardia, a rapid ventricular tachyarrhythmia episode, or an NST episode based on the electrocardiographic activity of heart 12 monitored via sensing module 86. For example, by means of at least some of electrodes 40, 42, 44, 46, 48, 50, 58, 62, 64, and 66 (e.g., Figure 1-2 ), the sensing module 86 may generate an electrocardiogram (ECG) or electrogram (EGM) signal representative of electrocardiographic activity. Alternatively, the sensing module 86 may be coupled to sensing electrodes (such as electrodes that are separate from the stimulation electrodes that deliver electrical stimulation to the heart 12) that are separate from the stimulation electrodes that deliver electrical stimulation to the heart 12. Figure 1-3 ), and can be coupled to leads 18, 20, 22 ( Figure 1-2 One or more leads different from those shown in ). The ECG signal may indicate depolarization of the heart 12.
[0080] For example, as previously described, in some examples, processor 80 can identify the presence of a tachyarrhythmia episode by detecting a threshold number of tachyarrhythmia events (e.g., RR or PP intervals of duration less than or equal to a threshold). In some examples, processor 80 can also identify the presence of a tachyarrhythmia episode by detecting variable coupling intervals between R waves of the cardiac signal. In one example, for example, the distal end of lead 18 can be configured to be positioned in or on the His bundle (atrioventricular bundle), and IMD 16 can be configured to deliver pacing via electrodes 40 and 42 to stimulate the His bundle during His bundle pacing.
[0081] Figure 6 is a plan view of an implantable medical lead including a helical fixation member for controlling bidirectional delivery of a therapeutic agent according to an example of the present disclosure. Figure 6As shown, an implantable medical lead 300 according to an example of the present disclosure includes an elongated body 302 extending between a proximal end 304 and a distal end 306 along a longitudinal axis 308, the longitudinal axis 308 being an imaginary line passing through the center of the elongated body 302 along the x-axis direction (i.e., from the proximal end 304 to the distal end 306). A connector assembly (not shown) is positioned at the proximal end 304 of the elongated body 302 to electrically connect the lead 300 to the connector block 34, as shown above. An electrode in the form of a helical fixing member 310, for example, is attached to the lead body 302 and extends from the distal end 306 of the elongated lead body 302. Specifically, the helical fixation member 310 extends from a proximal end 311 to a distal end 313 , wherein the proximal end 311 of the helical fixation member 310 is wound around the distal end 306 of the lead body 302 to securely attach the proximal end 311 of the helical fixation member 310 to the distal end 306 of the lead body 302 .
[0082] The helical fixation member 310 actively fixes the distal end 306 of the elongated body 302 at the desired implantation site. The helical fixation member 310 doubles as an electrode to which pacing pulses may be delivered, such as via the pulse generator 84, and to which cardiac electrical function may be sensed, such as via the sensing module 86. In one example, the helical fixation member 310 may be a helical hollow electrode in the form of a helically wound capillary having an outer diameter of approximately 0.008-0.015" and an inner diameter of approximately 0.004". Materials used to form the helical fixation member 310 include, but are not limited to, pure tantalum or platinum-iridium alloys, and may be coated with a conductive coating of titanium nitride.
[0083] exist Figure 6 In the example shown, the helical fixation member 310 includes a plurality of concentric turns around a central axis 312 that is aligned with the longitudinal axis 308 of the elongated body 302. The helical fixation member 310 is wound around the central axis 312 in a counterclockwise direction, thereby defining an outer surface 314 and an inner surface 316 of the helical fixation member 310. The outer surface 314 of the helical electrode 310 is configured to engage with a catheter (not shown) that can be used to guide the lead 300 to a desired implantation site, while the inner surface 316 of the helical electrode 310 faces the central axis 312 and is configured to cooperate with a guide wire (not shown) that can be used to guide the lead 300 to the implantation site. As known in the art, a guide wire can be used in addition to or instead of a catheter.
[0084] The helical fixing member 310 is configured to fix the distal end 306 of the elongated body 302 at the desired implantation site. To achieve this, the distal end 313 of the helical fixing member 310 includes a tissue piercing tip 318, which can be referred to as a "chisel tip" due to its shape. In order to fix the distal end 306 of the lead 300 at the desired implantation site, the helical fixing member 310 is positioned at the desired implantation site and rotated to "screw in" the tip 318 to pierce the surface tissue of the site, and after the helical fixing member 310 is rotated one or more times, the helical fixing member 310 is further advanced in the tissue at the desired implantation site, which can be, for example, the cardiac vasculature. The mechanism for moving the helical fixing member 310 is well known to those skilled in the art, but is generally activated by rotating a connector pin located at the proximal end 304 of the lead 300. The tip 318 includes a sharp edge that is used to facilitate the introduction of the tip 318 into the desired implantation site. While the remainder of the following description refers to the cardiovascular system or tissue and interchangeable implantation sites, it should be understood that implantable medical lead 300 according to the present disclosure is also suitable for use at other implantation sites within the body.
[0085] Figure 7 is a schematic diagram of a helical fixation member for controlled bidirectional delivery of a therapeutic agent according to an example of the present disclosure. Figure 7 As shown, the helical fixation member 310 includes a proximal delivery port 320 and a distal delivery port 322, both of which are in fluid communication with an inner cavity 324 (partially shown in phantom) within the helical fixation member 310, which extends from the proximal end 311 of the helical fixation member 310 to the distal end 313 and forms the inner diameter of the helical fixation member 310. In one example, both the proximal delivery port 320 and the distal delivery port 322 can have a diameter of approximately 0.0005-0.004 inches. However, for example, in some examples, the diameters of the proximal delivery port 320 and the distal delivery port 322 can have different values, as described below.
[0086] As a result, once the helical fixation member 310 is fixed within tissue such as cardiac tissue, a therapeutic agent such as a steroid can be bidirectionally released from the helical fixation member 310 within the cardiac tissue through the proximal delivery port 320 and the distal delivery port 322. More specifically, to enable controlled bidirectional release of the therapeutic agent, the proximal delivery port 320 is spaced apart from the distal delivery port 322 by a distance 326, wherein no additional delivery port is positioned within the distance 326 separating the distal delivery port 320 from the proximal delivery port 322. In one example, the steroid can be dexamethasone, beclomethasone, or a polymer mixture thereof.
[0087] Figure 8 is a schematic diagram of a helical fixation member for controlled bidirectional delivery of a therapeutic agent according to an example of the present disclosure. Figure 8 As shown, according to an example of the present disclosure, the distance 326 separating the proximal delivery port 320 and the distal delivery port 322 of the electrode 310 is configured so that the proximal delivery port 320 of the electrode 310 is positioned within the endothelial layer 328 of the tissue, and the distal delivery port 322 is positioned within the layer of myocardial tissue 330 below the endothelial layer 328. For example, the distance 326 between the proximal delivery port 320 and the distal delivery port 322 may be in the range of 2 mm to 12 mm. In one example, the distance 326 between the proximal delivery port 320 and the distal delivery port 322 may be approximately 8 mm.
[0088] Thus, the electrode 310 of the present disclosure enables a more targeted and controlled delivery of the therapeutic agent 332 near the distal end 306 of the lead 300 along the top surface 336 of the cardiac tissue at the implantation site and within the first fusion region 334 located within the endothelial layer 328 of the tissue. In addition, the therapeutic agent 332 is delivered via the distal delivery port 322 within a separate second fusion region 336 located at the distal end 313 of the helical electrode 310 and within the myocardial tissue 330. Since the therapeutic agent 332 is not delivered directly from the electrode 310 to the myocardial tissue 330 along the space 326 between the proximal delivery port 320 and the distal delivery port 322, but is controlled to be delivered only within the first fusion region 334 and the second fusion region 338, the electrode 310 of the present disclosure is configured to deliver the therapeutic agent 332 using a more controlled bidirectional release of the therapeutic agent 332.
[0089] In another example, the diameters of the proximal delivery port 320 and the distal delivery port 322 may have different values so that the amount of therapeutic agent delivered via one delivery port may be different relative to the other port. For example, it may be desirable to deliver the therapeutic agent from the proximal delivery port 320 at a greater rate than the amount delivered from the distal delivery port 322, resulting in a greater amount of agent delivered to the first fusion region 334 than the amount of therapeutic agent delivered to the second fusion region 336. Thus, in this example, the diameter of the proximal delivery port 320 will be configured to be greater than the diameter of the distal delivery port 322. In another example, it may be desirable to deliver the therapeutic agent from the proximal delivery port 320 at a lesser rate than the amount delivered from the distal delivery port 322, resulting in a greater amount of agent delivered to the second fusion region 336 than the amount of therapeutic agent delivered to the first fusion region 334. Thus, in this example, the diameter of the proximal delivery port 320 will be configured to be less than the diameter of the distal delivery port 322.
[0090] By being configured to enable a more controlled bi-directional release of the therapeutic agent 332, the present disclosure provides a more targeted and controlled method to ensure that the therapeutic agent 332 is delivered to minimize the inflammatory response in specific target areas of tissue where inflammation is most likely to occur. For example, the present disclosure ensures that the therapeutic agent 332 is delivered to the endothelial layer 328 of the tissue in the area where the distal end 306 of the lead 300 contacts the top surface 336 of the cardiac tissue at the implantation site. By enabling controlled delivery of the therapeutic agent to be delivered in two separate specific fusion areas 334 and 338, the total fusion area can be reduced and more targeted, thereby minimizing the amount of therapeutic agent 332 delivered, extending the period of time that the therapeutic agent 332 continues to be released, and enabling a more controlled and targeted reduction in inflammation that may occur.
[0091] In addition, this controlled bidirectional release of the present disclosure minimizes the damage to the strength of the electrode 310 that would occur if the number of delivery ports was increased to greater than the two delivery ports described, thereby enhancing the ability of the electrode 310 to more easily penetrate the tissue at the implant site and further reducing the amount of inflammation that occurs in specific selected targeted problem areas of the implant site. In addition, by only spacing the proximal delivery port 320 from the distal delivery port 322 by the above distance 326, and without a delivery port positioned along the electrode 310 within the distance 326 between the proximal delivery port 320 and the distal delivery port 322, the delivery of the therapeutic agent according to the present disclosure simplifies the capillary filling of the electrode 310.
[0092] Fig. 9 is a conceptual diagram illustrating an exemplary medical device system for delivering a therapeutic agent consistent with examples of the present disclosure. Fig. 9 As shown, a system 400 with bidirectional controlled release of a therapeutic agent in accordance with the present disclosure may include one or more leadless pacemaker devices 402 configured to be positioned within a right atrium 404 of a heart 406 of a patient 408, within a right ventricle 410 of the patient 408, or both, as shown in FIG. Fig. 9 The leadless pacemaker device 402 can be configured to monitor electrical activity of a heart 406 of a patient 408 and / or provide electrical therapy to the heart 406 .
[0093] Fig.10 is an example according to the present disclosure Fig. 9 Conceptual diagram of an exemplary medical device. Fig.10As shown, the leadless pacemaker device 402 includes a housing 412 and a helical fixation member 414 similar to the helical fixation member 310 described above, which is configured to connect (e.g., anchor) the leadless pacemaker device 402 to the heart 406. In some examples, the housing 412 can have a cylindrical shape that is pill-shaped, extending from a proximal end 416 to a distal end 418. In addition, the leadless pacemaker device 402 includes a ring electrode 420 positioned at the proximal end 416 of the housing 412 and one or more tip electrodes 422 positioned at the distal end 418 of the housing 412. In this manner, the ring electrode 420 and the tip electrode 422 can be employed by the leadless pacemaker device 420 for sensing electrical activity of the heart 406 and / or delivering electrical stimulation to the heart 406. The ring electrode 420 and the tip electrode 422 may be spaced apart a sufficient distance to be able to detect various electrical signals generated by the heart 406, such as P waves generated by the atria and R waves generated by the ventricles. In one embodiment, for example, the ring electrode 420 and the tip electrode 422 may be spaced apart from each other by at least 17 mm. Although the ring electrode 420 is shown as a cylindrical electrode wrapped around the housing 412, the ring electrode 420 may include other geometric shapes. In addition, although Fig.10 The leadless pacemaker device 402 shown in FIG. 4 includes multiple electrode tip electrodes 422, but in another embodiment, the leadless pacemaker device can include only a single electrode (not shown) that is centrally located at a region 424 of the distal end 418 of the housing 412. In some examples, the housing 412 can be formed of a conductive material. In these examples, the housing 412 can serve as an electrode of the leadless pacemaker device 402. Additionally, in some examples, the helical fixation member 414 can form an active electrode, or include an active electrode formed thereon, such as having an active electrode positioned along the distal end 440 of the helical fixation member 414, and can be used for multi-site leadless pacing.
[0094] The housing 412 houses the electronic components of the leadless pacemaker device 402. The electronic components may include any discrete and / or integrated electronic circuit components that implement analog and / or digital circuits capable of producing the functions attributed to the leadless pacemaker device 402 described herein. For example, the housing 412 may house electronic components that sense electrical activity via the ring electrodes 420 and the tip electrodes 422 and / or deliver electrical stimulation via the ring electrodes 420 and the tip electrodes 422. In addition, the housing 412 may also include a memory that includes instructions that, when executed by one or more processing circuits housed within the housing 412, cause the leadless pacemaker device 402 to perform various functions attributed to the leadless pacemaker device 402. The housing 412 may also house sensors that sense a physiological condition of the patient 408, such as an accelerometer and / or a pressure sensor.
[0095] In some examples, the housing 412 can house a communication module that enables the leadless pacemaker device 402 to communicate with other electronic devices such as a programmer or other external patient monitor. In some examples, the housing 412 can house an antenna for wireless communication. The housing 412 can also include a power source, such as a battery. The electronic components included in the housing 412 are described in further detail below.
[0096] Similar to the helical fixation member 310 described above, the helical fixation member 414 rotates in a counterclockwise direction about a central axis 426 and includes an inner surface 428 facing the central axis 426 and an outer surface 430 facing an outer region surrounding the helical fixation member 414. The helical fixation member 414 includes a proximal delivery port 432 and a distal delivery port 434, both of which are connected to the inner cavity 424 ( Figure 7 440 of the helical fixing member 310, the lumen 424 extends from the proximal end 438 of the helical fixing member 414 to the distal end 440 and forms the inner diameter of the helical fixing member 414. In one example, both the proximal delivery port 432 and the distal delivery port 434 may have a diameter of approximately 0.0005-0.004 inches. However, for example, in some examples, the diameters of the proximal delivery port 432 and the distal delivery port 434 may have different values, as described below. In either case, i.e., the diameters are the same or different, according to one example, the sum of the two diameters may be less than or equal to the diameter of the lumen 324 of the fixing member 310.
[0097] As a result, once the helical fixation member 414 is fixed within tissue such as cardiac tissue, a therapeutic agent such as a steroid can be bi-directionally released from the helical fixation member 414 within the cardiac tissue through the proximal delivery port 432 and the distal delivery port 434. More specifically, to enable controlled bi-directional release of the therapeutic agent, the proximal delivery port 432 is spaced apart from the distal delivery port 434 by a distance similar to the distance 326 described above, wherein no additional delivery ports are positioned within the distance that the distal delivery port 434 is spaced apart from the proximal delivery port 432. As described above, the distance that the proximal delivery port 432 is spaced apart from the distal delivery port 434 is configured such that the proximal delivery port 432 is positioned within the endothelial layer 328 of the tissue and the distal delivery port 434 is positioned within the layer of the myocardial tissue 330 below the endothelial layer 328. For example, the distance between the proximal delivery port 432 and the distal delivery port 434 can be in the range of 2 mm to 12 mm. In one example, the distance between the proximal delivery port 432 and the distal delivery port 434 can be approximately 8 mm. In one example, the steroid can be dexamethasone, beclomethasone, or a polymer mixture thereof.
[0098] like Fig.10As shown, in one example where the tip electrode 422 is positioned about the distal end 418 of the housing 412 and positioned outside of the helical fixation member 414, the proximal delivery port 432 may be configured to be positioned along the outer surface 430 of the helical fixation member 414 to control the delivery of the therapeutic agent so that the therapeutic agent is released along the tip electrode 422. However, in another example where the single electrode is centrally positioned along the region 424 of the distal end 418 of the housing 412, the proximal delivery port 432 may be configured to be positioned along the inner surface 428 of the helical fixation member 414 to control the delivery of the therapeutic agent so that the therapeutic agent is released along the tip electrode.
[0099] In addition, as described above, the diameters of the proximal delivery port 432 and the distal delivery port 434 can be the same, or can have different values, such that the amount of therapeutic agent delivered via one delivery port can be different relative to the other port. For example, the diameter of the proximal delivery port 432 can be configured to be larger than the diameter of the distal delivery port 434, such that the therapeutic agent can be delivered from the proximal delivery port 432 at a rate greater than the amount delivered from the distal delivery port 434, thereby resulting in a greater amount of agent delivered along the tip electrode 422 and / or within the first fusion region 334 than the amount of therapeutic agent delivered along the distal end 440 of the helical fixation member 414 and / or the second fusion region 336. Therefore, in this example, the diameter of the proximal delivery port 432 will be configured to be larger than the diameter of the distal delivery port 434. According to one example, in either case, i.e., the diameters of the proximal delivery port 432 and the distal delivery port 434 are the same or the diameters of the proximal delivery port 432 and the distal delivery port 434 are different, the sum of the diameters of the proximal delivery port 432 and the distal delivery port 434 is configured to be less than or equal to the diameter of the inner cavity 436 of the fixing member 414.
[0100] Fig.11 is a functional block diagram illustrating an exemplary configuration of a leadless pacemaker device according to an example of the present disclosure. Fig.11 As shown, the leadless pacemaker device 402 may include a processing module 500, a memory 502, a signal generator module 504, an electrical sensing module 506, a communication module 508, a sensor 510, and a power source 512. The power source 512 may include a battery, such as a rechargeable or non-rechargeable battery.
[0101] The modules included in the leadless pacemaker device 402 represent functions that may be included in the atrial device 100 of the present disclosure. Similar or identical modules and functions may also be included in a ventricular pacemaker device, which may be provided as part of a dual-chamber leadless pacemaker system for implantation and use in at least one atrium and at least one ventricle of the heart, as discussed in U.S. Patent Application Publication No. 2014 / 0121720, which is incorporated herein by reference. The modules of the present disclosure may include any discrete and / or integrated electronic circuit components that implement analog and / or digital circuits capable of producing the functions attributed to the modules herein. For example, the modules may include analog circuits, such as amplification circuits, filtering circuits, and / or other signal conditioning circuits. The modules may also include digital circuits, such as combinational or sequential logic circuits, memory devices, and the like. The memory may include any volatile, non-volatile, magnetic, or electrical media, such as random access memory (RAM), read-only memory (ROM), non-volatile RAM (NVRAM), electrically erasable programmable ROM (EEPROM), flash memory, or any other memory device. Furthermore, the memory may include instructions that, when executed by one or more processing circuits, cause the modules to perform the various functions attributed to the modules herein.
[0102] Functions attributed to modules herein may be embodied as one or more processors, hardware, firmware, software, or any combination thereof. Describing different functions as modules is intended to highlight different functional aspects, and this does not necessarily mean that these modules must be implemented by separate hardware or software components. On the contrary, functions associated with one or more modules may be performed by separate hardware or software components, or integrated in common or separate hardware or software components.
[0103] The processing module 500 can communicate with the memory 502. The memory 502 can include computer-readable instructions that, when executed by the processor 500, cause the processing module 500 to perform various functions attributed to the processing module 500 herein. The memory 502 can include any volatile, nonvolatile, magnetic, or electrical medium, such as RAM, ROM, NVRAM, EEPROM, flash memory, or any other digital medium. For example, the memory 502 can include pacing instructions and values, such as a baseline atrial pacing rate, a baseline atrial pacing interval, and a baseline AV interval. The pacing instructions and values can be updated by a programmer. The pacing instructions included in the memory 502 can cause the leadless pacing device 402 to operate as described in U.S. Patent Application Publication No. 2014 / 0121720, which was previously incorporated herein by reference.
[0104] The processing module 500 can communicate with the signal generator module 504 and the electrical sensing module 506. The signal generator module 504 and the electrical sensing module 506 are electrically coupled to the ring electrodes 420 and the tip electrodes 422. The electrical sensing module 506 is configured to monitor signals from the ring electrodes 420 and the tip electrodes 422 to monitor the electrical activity of the heart 406. The signal generator module 504 is configured to deliver electrical stimulation to the heart 404 via the ring electrodes 420 and the tip electrodes 422.
[0105] The processing module 500 can control the signal generator module 504 to generate and deliver electrical stimulation to the atrium 404 via the ring electrodes 420 and the terminal electrodes 422. The electrical stimulation may include pacing pulses. The processing module 500 can control the signal generator module 504 to perform electrical stimulation therapy according to one or more atrial therapy programs including pacing instructions and values, which can be stored in the memory 502.
[0106] The electrical sensing module 506 may include circuitry to acquire electrical signals. The electrical signals acquired by the electrical sensing module 506 may include intrinsic cardiac electrical activity, such as intrinsic atrial and / or intrinsic ventricular electrical activity. The electrical sensing module 506 may filter, amplify, and digitize the acquired electrical signals to generate raw digital data. The processing module 500 may receive the digitized data generated by the electrical sensing module 506. In some examples, the processing module 500 may perform various digital signal processing operations on the raw data, such as digital filtering.
[0107] Processing module 500 may sense cardiac events based on data received from electrical sensing module 506. For example, processing module 500 may sense atrial events based on data received from electrical sensing module 506. In some examples, processing module 500 may sense ventricular activation based on data received from electrical sensing module 506. For example, processing module 500 may detect an R wave indicative of ventricular activation based on data received from electrical sensing module 506.
[0108] By being configured to enable more controlled bi-directional release of therapeutic agents, the present disclosure provides a more targeted and controlled method to ensure delivery of therapeutic agents to minimize inflammatory responses in specific target areas of tissue where inflammation is most likely to occur, such as within the endothelial layer of tissue, which is located in the area where the tip electrode 422 contacts the top surface 336 of the cardiac tissue at the implantation site. By enabling controlled delivery of therapeutic agents to be delivered within two separate specific fusion areas 334 and 338, the total fusion area can be reduced and more targeted, thereby minimizing the amount of therapeutic agent 332 delivered, extending the period of time over which the therapeutic agent 332 continues to be released, and enabling a more controlled and targeted reduction in inflammation that may occur.
[0109] In addition, this controlled bidirectional release of the present disclosure minimizes the damage to the strength of the helical fixation member 414 that would occur if the number of delivery ports was increased to greater than the two delivery ports described, thereby enhancing the ability of the helical fixation member 414 to more easily penetrate the tissue of the implantation site and further reducing the amount of inflammation that occurs in the specific selected targeted problem areas of the implantation site. In addition, by only spacing the proximal delivery port 432 from the distal delivery port 434 by the above distance, and without a delivery port positioned along the helical fixation member 414 within the distance between the proximal delivery port 432 and the distal delivery port 434, the delivery of the therapeutic agent according to the present disclosure simplifies the capillary filling of the helical fixation member 414.
[0110] All references cited herein and disclosed herein are hereby expressly incorporated by reference into the present invention, except where they are directly inconsistent with the present disclosure. The illustrative embodiments of the present disclosure are discussed, and reference is made to possible variations within the scope of the present disclosure. These and other modifications and changes in the present disclosure are obvious to those skilled in the art, do not depart from the scope of the present disclosure, and it should be understood that the present disclosure is not limited to the illustrative embodiments set forth herein. Accordingly, the present disclosure is limited only by the claims provided herein.
Claims
1. An implantable medical device comprising: a housing extending from a proximal end to a distal end; a sensing module, the sensing module being within the housing to sense a cardiac signal; a stimulation generator within the housing to deliver cardiac therapy in response to sensed cardiac signals; A fixing member having a proximal end and a distal end, wherein the proximal end of the fixing member is coupled to the distal end of the housing and extends from the distal end of the housing, the fixing member comprising: and a first delivery port and a second delivery port, wherein the first delivery port and the second delivery port are used to release a therapeutic agent from the fixing member to the patient's tissue, wherein the first delivery port is positioned along the proximal end of the fixing member to deliver the therapeutic agent to endothelial cells along the endothelial layer of the tissue when the proximal end of the shell contacts the top surface of the patient's tissue, and the second delivery port is positioned along the distal end of the fixing member and is spaced a certain distance from the first delivery port to deliver the therapeutic agent to myocardial tissue within the myocardial layer of the tissue, and wherein no delivery port is positioned within the distance separating the second delivery port from the first delivery port.
2. The implantable medical device according to claim 1, wherein: The implantable medical device includes a leadless pacemaker device.
3. The implantable medical device according to claim 1, wherein: The first delivery port has a first diameter and the second delivery port has a second diameter, and wherein the first diameter is approximately equal to the second diameter.
4. The implantable medical device according to claim 1, wherein: The first delivery port has a first diameter and the second delivery port has a second diameter, and wherein the first diameter is greater than the second diameter.
5. The implantable medical device according to claim 1, wherein: The first delivery port has a first diameter and the second delivery port has a second diameter, and wherein the first diameter is smaller than the second diameter.
6. The implantable medical device according to claim 1, wherein: The fixation member comprises a helical fixation member, and the implantable medical device further comprises: One or more electrodes for at least one of sensing cardiac signals and delivering cardiac therapy located at the distal end of the housing, wherein the first delivery port is positioned along an outer surface of the helical fixation member and the one or more electrodes are positioned outside of the helical fixation member.
7. The implantable medical device according to claim 1, wherein: The fixation member comprises a helical fixation member having an inner surface and an outer surface, and wherein the first delivery port and the second delivery port are both located along one of the inner surface and the outer surface of the helical fixation member.
8. The implantable medical device according to claim 1, wherein: The fixation member comprises a helical fixation member having an inner surface and an outer surface, and wherein the first delivery port is located along the outer surface of the helical fixation member and the second delivery port is located along the inner surface of the helical fixation member.
9. The implantable medical device according to claim 8, wherein: The first delivery port has a first diameter and the second delivery port has a second diameter, and wherein the first diameter is greater than the second diameter.
10. The implantable medical device according to claim 1, wherein: The fixation member comprises a helical fixation member, and the implantable medical device further comprises: One or more electrodes for at least one of sensing cardiac signals and delivering cardiac therapy located at the distal end of the housing, wherein the first delivery port is positioned along an inner surface of the helical fixation member and the one or more electrodes are positioned within the interior of the helical fixation member.
11. A fixation member for use with an implantable medical device, the fixation member extending from a distal end of a lead body or housing, the fixation member comprising: a helical body having a proximal end and a distal end and configured to be fixedly positioned within cardiac tissue; an inner lumen extending within the helical body and extending from the proximal end to the distal end; a first delivery port positioned along a proximal end of the helical body and in fluid communication with the lumen to deliver a therapeutic agent within the lumen to the cardiac tissue; as well as A second delivery port, the second delivery port is positioned along the distal end of the spiral body and is connected to the inner cavity fluid to deliver the therapeutic agent to the cardiac tissue, the second delivery port is spaced a certain distance from the first delivery port so that when the distal end of the lead body or the shell contacts the top surface of the patient's tissue, the therapeutic agent is delivered to endothelial cells along the endothelial layer of the cardiac tissue via the first delivery port, and the therapeutic agent is delivered to myocardial tissue within the myocardium of the cardiac tissue via the second delivery port, and wherein no delivery port is positioned within the distance between the first delivery port and the second delivery port.
12. The fixing member according to claim 11, characterized in that The first delivery port has a first diameter and the second delivery port has a second diameter, and wherein the first diameter is approximately equal to the second diameter.
13. The fixing member according to claim 11, characterized in that The first delivery port has a first diameter and the second delivery port has a second diameter, and wherein the first diameter is greater than the second diameter.
14. The fixing member according to claim 11, characterized in that The first delivery port has a first diameter and the second delivery port has a second diameter, and wherein the first diameter is smaller than the second diameter.
15. The fixing member according to claim 11, characterized in that The fixation member includes electrodes for at least one of sensing cardiac signals and delivering cardiac therapy.
16. The fixing member according to claim 11, characterized in that The fixing device comprises a spiral fixing member.
